Cue Biopharma, Inc. Repayments of Debt
Cue Biopharma, Inc. (CUE) reported Repayments of Debt of $100.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2025-05-12
- Cue Biopharma, Inc. repayments of debt for the quarter ending 2025-03-31 was $100.00K, a 0.00% change year-over-year.
- Cue Biopharma, Inc. repayments of debt for the quarter ending 2024-09-30 was $100.00K, a 203.03% increase year-over-year.
- Cue Biopharma, Inc. repayments of debt for the quarter ending 2024-06-30 was $33.00K, a 0.00% change year-over-year.
- Cue Biopharma, Inc. repayments of debt for the quarter ending 2024-03-31 was $100.00K.
| Period end | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month |
|---|---|---|---|
| 2025-03-31 | $100.00K 10-Q · filed 2025-05-12 | ||
| 2024-09-30 | $100.00K 10-Q · filed 2024-11-14 | $133.00K derived: sum of 2 quarters · filed 2024-11-14 | $100.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $33.00K 10-Q · filed 2024-08-14 | $65.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-12 | ||
| 2023-09-30 | $33.00K 10-Q · filed 2024-11-14 | $66.00K derived: sum of 2 quarters · filed 2024-11-14 | $98.00K 10-Q · filed 2024-11-14 |
| 2023-06-30 | $33.00K 10-Q · filed 2024-08-14 | $65.00K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |